A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age

Highlights ► A postmarketing study evaluated the safety of LAIV in children 5–17 years of age. ► 43,702 LAIV recipients were matched with TIV-vaccinated and unvaccinated children. ► Rates of medically attended events (MAEs) were calculated for eligible children. ► Medically attended event rate diffe...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-04, Vol.30 (19), p.2989-2998
Main Authors: Baxter, Roger, Toback, Seth L, Sifakis, Frangiscos, Hansen, John, Bartlett, Joan, Aukes, Laurie, Lewis, Ned, Wu, Xionghua, Ambrose, Christopher S
Format: Article
Language:English
Subjects:
Adolescent
Age
Allergy and Immunology
Anaphylaxis
Ann Arbor strain
Asthma
Attention deficit hyperactivity disorder
Bell's palsy
Child
Child, Preschool
Children
clinical trials
Drug-Related Side Effects and Adverse Reactions - epidemiology
Female
Hospitalization - statistics & numerical data
Humans
Immunization
Influenza
Influenza vaccine
Influenza Vaccines - administration & dosage
Influenza Vaccines - adverse effects
Live attenuated influenza vaccine
Male
Mortality
Postmarketing safety
Product Surveillance, Postmarketing
Prospective Studies
Respiratory diseases
Safety
Self
Side effects
Statistics
Survival Analysis
United States
Vaccines
Vaccines, Attenuated - administration & dosage
Vaccines, Attenuated - adverse effects
Wheezing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► A postmarketing study evaluated the safety of LAIV in children 5–17 years of age. ► 43,702 LAIV recipients were matched with TIV-vaccinated and unvaccinated children. ► Rates of medically attended events (MAEs) were calculated for eligible children. ► Medically attended event rate differences did not suggest a safety signal with LAIV in eligible children. ► Rates of SAEs were similar between LAIV and control groups.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.02.039